Latest News

Magnesium sulfate shown to reduce risk of cerebral palsy in premature babies


 

Accelerate uptake

Uptake of new evidence or guidelines is often “slow” due to practical barriers, lack of knowledge, and need for behavior change, and can “take decades to become embedded” in perinatal clinical practice, expressed the authors, which in turn comes at a “high clinical and economic cost.”

Karen Luyt, professor in neonatal medicine, University of Bristol, said: “The PReCePT national quality improvement program demonstrates that a collaborative and coordinated perinatal implementation program supporting every hospital in England can accelerate the uptake of new evidence-based treatments into routine practice, enabling equitable health benefits to babies and ultimately reductions in lifetime societal costs.”

The authors said the PReCePT model “may serve as a blueprint for future interventions to improve perinatal care.”

Professor Lucy Chappell, chief executive officer of the National Institute for Health and Care Research, said: “This important study shows the impact of taking a promising intervention that had been shown to work in a research setting and scaling it up across the country. Giving magnesium sulfate to prevent cerebral palsy in premature babies is a simple, inexpensive intervention that can make such a difference to families and the health service.”

Prof. Macleod added: “We are pleased to have played a part in helping get this cheap yet effective treatment to more babies.”

This work was jointly funded by the National Institute for Health and Care Research Applied Research Collaboration West and the AHSN Network funded by NHS England. The Health Foundation funded the health economics evaluation. The authors declare that the study management group has no competing financial, professional, or personal interests that might have influenced the study design or conduct.

A version of this article first appeared on Medscape UK.

Pages

Recommended Reading

Compulsively checking social media linked with altered brain patterns in teens
MDedge Family Medicine
FDA approves second antiamyloid for Alzheimer’s disease
MDedge Family Medicine
What to know about newly approved Alzheimer’s drug
MDedge Family Medicine
ADHD beyond medications
MDedge Family Medicine
Chronic pain patients swapping opioids for medical cannabis
MDedge Family Medicine
Telehealth parent-child interaction therapy improved behavior in children with developmental delay
MDedge Family Medicine
Hearing loss strongly tied to increased dementia risk
MDedge Family Medicine
Some BP meds tied to significantly lower risk for dementia, Alzheimer’s
MDedge Family Medicine
Long COVID comes into focus, showing older patients fare worse
MDedge Family Medicine
Postconcussion symptoms tied to high risk of depression
MDedge Family Medicine